

SENSIMED AG receives CE Mark for monitoring intraocular pressure (IOP) continuously to aid in diagnosis and in treatment of glaucoma.

Lausanne, 12th March 2009 – SENSIMED AG announced that it has received the CE Mark for the SENSIMED Triggerfish[®] system, which is design to monitor continuously intraocular pressure up to 24 hours. Today, on the World Glaucoma Day, SENSIMED Triggerfish[®] system brings a breakthrough solution to the glaucoma community that helps diagnosis and treatment of the glaucoma disease which hand reducing the risk of blindness. The system is composed with a soft hydrophilic silicone disposable contact lens embedding a MEMS sensor (micro electro-mechanical system) and a telemetry microprocessor.

Glaucoma is an asymptomatic, progressive and irreversible disease which leads to blindness unless adequate treatment is provided. Glaucoma is the second most common cause of blindness worldwide and affects about 68 million people. Abnormal intraocular pressure is one of known causes of glaucoma. This behavior is individual, has transient peaks and varies significantly over a 24-hours period.

“With one of two glaucoma patient undiagnosed and one of three under inadequate treatment, we believe the SENSIMED Triggerfish[®] will be a great contribution to help ophthalmologists diagnose and treat their glaucoma patients.” said Jean-Marc Wismer, CEO of SENSIMED. “SENSIMED will not only revolutionize the way glaucoma is diagnosed and treatment is managed, but will also make a contribution to a deeper understanding of its progression. A better understanding of how pressure fluctuates during night and day in a patient suffering from glaucoma will lead, for the first time, to more efficient and personalized drug delivery. The breakthrough potential of the solution is enormous and confirmed by the eagerness of our key opinion leaders.”

“CE mark is an important milestone in SENSIMED’s initiative to develop and market the SENSIMED Triggerfish[®]. In 2009 SENSIMED will focus on clinical trials in well renowned centers in the European Union (EU) and will market the SENSIMED Triggerfish[®] system in selected countries.” said Malgosia Iwankowska, VP Sales and Marketing of SENSIMED. In the United States, SENSIMED Triggerfish[®] solution is currently under Food and Drug Administration (FDA) review.

In addition to the medical device system, SENSIMED has developed a full, generic telemetry solution which can be adapted to interface various types of sensors for a variety of applications. The principle is to enable in-situ measurement without physical connection nor power supply on the sensing site. An external system will send RF (radio-frequency) power to the sensing site and receive in return measurement information.

About SENSIMED:

Established in 2003, SENSIMED AG is a Swiss company with its principal focus on design, development and commercialization of integrated micro-systems for medical devices. SENSIMED AG is a spin-off of well renowned Swiss Federal Institute of Technology (EPFL) and grows within a world-leading cluster for medical devices in the lake of Geneva area. SENSIMED AG has developed a new, patented, non-invasive solution that will significantly improve identification and treatment of glaucoma disease by monitoring intraocular pressure around the clock.

Contact information: Jean-Marc Wismer, CEO